New Century Healthcare Holding Co. Ltd. 1518
HKEX · Hong Kong SAR China · Health Services
HKD 0.1860+0.00 (+0.54%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.
Australia’s inflation rate recently reached 4%, and the Reserve Bank lifted its cash rate target to 4.60%, partly linked to the artificial intelligence boom. Higher funding costs can pressure many sectors. Healthcare groups using AI to improve diagnoses, tailor treatments and run hospitals more efficiently could still attract attention. This article highlights three Australian AI healthcare stocks from our focused screener that investors may want on their watchlist. The three stocks below are...
The analyst fair value estimate for Amneal Pharmaceuticals has shifted from US$22.00 to about US$22.71 per share, reflecting updated price targets within the US$20 to US$27 range that are guiding much of the current discussion. Analysts are tying these targets to how effectively Amneal Pharmaceuticals turns its new products, biosimilars platform, and recent acquisitions into durable earnings power. As you read on, you will see how this evolving narrative may shape your own view of the stock’s...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.